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Abstract We determined the cardiologic features of chil-
dren with MPS I, II and VI, and evaluated the effect of
enzyme-replacement therapy (ERT) on cardiac disease.
Twenty-four children aged 1-18 years with MPS I, II or VI
were prospectively evaluated with echocardiogram and elec-
trocardiogram from the start of enzyme-replacement therapy
up to 6 years of treatment. At start of therapy, 66% had
abnormal cardiac geometric features. Left-ventricular mass
index (LVMI) was increased in half of the patients, due
mainly to concentric hypertrophy in MPS I and II and to
eccentric hypertrophy in MPS VI. Regurgitation was most
severe in a subgroup of young MPS VI patients (<5 years) at
the mitral valve. At baseline, all patients had abnormal
valves. The ECG showed no clear rhythm or conduction
abnormalities; neither, in most patients, did it reflect the
hypertrophy. After ERT, the LVMI Z-score normalized in
70% of the patients who had a Z-score>2. LVMI Z-scores
decreased significantly in patients with MPS I and MPS II
(p00.04 and p00.032). Despite ERT, valve regurgitation
increased in 60% of the patients. We conclude that all our
MPS patients have cardiac abnormalities. The most severe
cardiac disease was observed in a subgroup of young MPS
VI patients. While ERT had an effect on LVMI and IVSd, it
apparently had little or none on valve regurgitation.
Introduction
The mucopolysaccharidoses (MPS) are a group of lysosom-
al storage disorders, each caused by deficiency in one or
more specific lysosomal enzymes involved in degrading
glycosaminoglycans (Neufeld and Muenzer 2001). The
resulting intralysosomal storage of glycosaminoglycans
causes progressive disease that involves multiple organs,
including the heart. All MPS are rare diseases; in the Nether-
lands their combined birth prevalence is estimated to be 1 in
22,000 (Poorthuis et al. 1999). Cardiac involvement has
been reported for all forms of MPS, the most documented
abnormalities being regurgitation, stenosis and morphologic
changes of the cardiac valves, and cardiac hypertrophy
(Dangel 1998; Gross et al. 1988; Rigante and Segni 2002;
Wippermann et al. 1995). Recently, enzyme-replacement
therapy (ERT) was introduced for MPS types I, II and VI.
While this has alleviated several aspects of the disease, such
as joint-mobility, endurance, and lung function (Harmatz et
al. 2006; Muenzer et al. 2006; Wraith et al. 2007; Wraith et
al. 2004), it is unclear whether it affects the cardiac abnor-
malities (Braunlin et al. 2006; Fesslova et al. 2009). In a
cohort of patients with MPS I, II and VI we therefore
studied these abnormalities before the start of ERT, and the
effect of ERT upon them.
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Materials and methods
We prospectively studied 24 children with MPS I Hurler
syndrome (OMIM 607014), MPS I Scheie syndrome
(OMIM 607016), MPS II Hunter syndrome (OMIM
309900) and MPS VI Maroteaux-Lamy syndrome (OMIM
253200). The diagnosis of MPS was confirmed in all
patients by mutation analysis and enzyme assay on leuko-
cytes and fibroblasts. We subdivided the Hurler and Scheie
patients on base of clinical presentation in combination with
mutation anlaysis.
None of these patients had undergone hematopoietic stem
cell transplantation. Patients with MPS I received 0.58 mg/
kg/week intravenous laronidase (Aldurazyme ®, Genzyme
Corporation); MPS II patients received 0.5 mg/kg/week
intravenous idursulfase (Elaprase ®, Shire Pharmaceutical
Inc); and MPS VI patients received 1.0 mg/kg/week intra-
venous galsulfase (Naglazyme ®, BioMarin Pharmaceutical
Inc). The institutional review board approved the study
and all patients provided written informed consent before
participation.
A standardized assessment program was initiated to
prospectively investigate cardiovascular abnormalities
and function using a 12-lead electrocardiogram (ECG)
and detailed echocardiogram. Cardiologic assessments
were performed before the start of ERT and yearly there-
after, or more frequently if cardiologic abnormalities were
severe.
Echocardiographic studies were performed by an experi-
enced sonographer (JP) using a Philips iE33 xMAtrix Echo-
cardiography System, Philips Medical Systems, Andover,
MA, USA. Data were digitally stored and subsequently
analyzed by two researchers (MB, IF). The following
parameters were measured by 2D-guided M-mode tracing:
end-diastolic left-ventricular internal dimension (LVIDd);
inter-ventricular septum thickness in diastole (IVSd); left-
ventricular posterior wall thickness in diastole (LVPWd);
and shortening fraction (SF). These values were compared
with normal values according to Kampmann et al. (Kampmann
et al. 2000). The left-ventricular mass index (LVMI) was
calculated using the Devereux formula and indexed by body
surface area with normal values according to Poutanen et al.
(Poutanen and Jokinen 2007).
Diastolic filling was established using the E/A ratio by
measuring mitral-inflow as determined by pattern-peak early
filling (E) and late filling (A) velocities, and systolic function
using the shortening fraction (Eidem et al. 2004). An E/A
ratio<1 was considered abnormal. Specific attention was
paid to the morphology and thickness of the valves, and also
to valve regurgitation, which was determined according to
the recommendations of the American Society of Echocar-
diography (Zoghbi et al. 2003). Trivial valve regurgitation
was not considered abnormal.
The change over time in the thickness of the aortic and
mitral valve was established during ERT, the first and last
echocardiogram of every patient being studied by three
experienced cardiologists and echocardiographists (IF,
MvO, JP). The tricuspid and pulmononary valve could not
be evaluated for changes in thickness over time since the
imaging quality of these valves during follow-up was in-
consistent. To evaluate the valves during ERT, one addition-
al patient was excluded from the analysis, since his obesity
impaired the echo window.
Due to the inability to lie quietly at time of the echocar-
diogram, there were no complete baseline echocardiograms
of three patients (one MPS I Hurler and 2 MPS VI patients);
for each, we therefore used an echocardiogram made before
enzyme therapy as baseline value. The effects of enzyme
therapy could be reliably evaluated in 20 patients, with a
median follow-up of 104 weeks (range of treatment 48-
312 weeks of therapy). Four patients were excluded from
the analysis of the effect of ERT: two had received ERT for
less than one year; one had no reliable follow-up echocar-
diograms due to behavioural problems; and one had received
a mitral graft which was considered to be a co-intervention
bias.
Twelve-lead standard ECG’s were recorded using a
Mortara ELI 350, Mortara instrument Inc, Milwaukee,
USA. ECGs were analyzed by hand by a single observer
from a cardiologic core laboratory (Cardialysis BV). Pedi-
atric reference values were obtained from Park et al. and
corrected for age and heart rate. QT duration was corrected
for heart rate using Bazett's formula: QTc 0 QT / √(RR-
interval) (Park and Guntheroth 2006).
Every echocardiographic value obtained was transformed
into a Z-score calculated as the difference between the
observed value for the patient and the mean reference value
divided by the standard deviation from the reference value.
Z-scores >2 were considered abnormal. For every individual
and at group level, change over time was analyzed using
multiple linear regression with weeks of treatment as the
independent variable. A p-value < 0.05 was considered
significant. All statistical analyses were conducted using
SPSS version 15.0.
Results
Twenty-four patients were included in the study: 8 MPS I
patients (5 Hurler and 3 Scheie), 6 MPS II patients, and 10
MPS VI patients. Fourteen patients (56%) were Caucasian,
4 Arab (16%), 4 Turkish (16%), 1 Asian and 1 African.
Most patients in the MPS VI group (70%) were non-
Caucasian. Table 1 shows the first and latest main clinical
and cardiologic features of the echocardiograms per patient.
All abnormal values (Z >2) are printed in bold. The median
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Table 1 Baseline clinical and cardiologic features of 24 mucopolysaccharidosis patients
Pt Age at
baseline (yrs)
Sex MPS type Age at
diagnosis (yrs)
IVSd
start ERT
IVSd
after ERT
LVIDd
start ERT
LVIDd
after ERT
LVPWd
start ERT
LVPWd
after ERT
LVMI
start ERT
LVMI
after ERT
Hypertrophy
start ERT
E/A ratio
start ERT
SF
start ERT
Follow-up
(weeks)**
1 5 F IH 2 5.20 0.38 1.93 2.97 -0.13 -0.19 6.18 2.50 Concentric 1.30 26 312
2 1.3 F IH 0 1.37 -0.13 -0.04 -0.40 0.93 -0.27 -0.28 -1.54 0 1.10 36 311
3 4.4* M IH 1 8.00 *** -3.05 *** 2.24 *** 1.87 *** 0 0.74 43 104
4 4.8 M IH 1 3.47 1.56 0.93 -0.69 2.00 0.91 4.28 -0.13 Concentric 1.10 42 302
5 9.3† M IH 1 4.00 6.67 0.60 -0.58 4.27 4.82 6.68 6.94 Concentric 0.80 52 81
6 4.9 M IS 5 3.30 -0.13 -0.07 0.95 2.13 -0.59 2.89 -0.90 0 1.30 41 93
7 2.4 F IS 1 1.60 0.67 0.37 0.95 1.60 0.12 2.38 1.37 0 1.30 34 87
8 8.4 M IS 5 2.56 1.55 1.03 1.13 1.55 -0.79 1.62 1.71 0 1.70 32 259
9 10.8 M II 3 0.11 0.74 -0.41 -0.12 0.00 0.25 -0.62 -0.10 0 0.97 40 149
10 8.3 M II 2 0.33 1.11 -0.03 -0.69 -0.27 0.09 -0.32 -0.61 0 1.20 36 104
11 5.3 M II 3 3.56 2.22 -0.36 0.10 1.55 0.23 3.01 0.97 Concentric 1.20 36 116
12 1.0 M II p.n 2.88 -0.56 -0.36 0.30 -0.93 1.00 0.10 -0.03 0 1.40 35 159
13 2.3 M II 2 1.87 *** 0.50 *** 1.33 *** 1.62 *** 0 1.40 45 0
14 9.5 M II 6 4.0 0.78 0.75 0.57 2.00 -0.23 3.92 -0.23 Concentric 1.20 33 115
15 8 F VI 8 2.00 1.56 0.71 1.06 0.29 0 0.75 1.20 0 1.20 45 79
16 2.8* M VI 2 1.60 -0.40 1.85 5.50 2.40 -0.80 5.04 3.90 Eccentric 1.30 23 92
17 7.5 M VI 7 1.89 0.42 0.44 -1.57 1.90 1.67 1.50 -0.47 0 1.70 46 104
18 18.3 M VI 16 0.56 1.36 -2.85 -1.85 0.07 0.80 -1.59 -0.52 0 1.30 34 92
19 7.6 F VI 7 0.75 -0.33 0.06 1.28 -1.14 0.27 -0.81 0.36 0 1.50 35 53
20 5.9 M VI 5 0.38 1.00 1.68 1.68 -0.19 0.29 1.23 1.52 0 1.90 36 52
21 1.9 F VI 1 1.12 -0.67 5.00 3.00 0.80 -0.67 7.32 1.24 Eccentric 2.00 30 48
22 5.3* M VI 5 2.40 0,67 2.18 1.61 0.47 0.82 4.28 1.91 0 1.80 32 154
23 2.3 M VI 2 1.47 *** 1.85 *** 0.80 *** 3.01 *** 0 0.81 34 0
24 6.6* F VI 3 4.00 *** 6.93 *** 6.93 *** 26.4 *** Eccentric 1.70 36 144
M0Male F0Female; IVSd0 interventricular septum dimension at diastole; LVIDd0 left-ventricular internal dimension at diastole; LVPWd0 left-ventricular posterior wall diameter at diastole;
LVMI0 left-ventricular mass index; SF0shortening fraction; p.n.0prenatal diagnostic procedure. 00absent. Abnormal values are printed in bold
*first echocardiogram of these patients was inoperable due to uncooperative behaviour. The echocardiogram of patient number 3 was made at 26 weeks of ERT; that of patient number 16 was made
at 12 weeks of ERT; that of patient number 24 was made 20 weeks before ERT; and that of patient number 22 at 27 weeks before ERT
**the follow-up time was identical to the period that the patients were treated with ERT
***No follow-up echocardiogram available due to short follow-up time, behavioural problems or co-intervention bias
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age at diagnosis was 2.5 years (range 0-16 years); at start of
therapy it was 5.3 years (range 1-18 years). Age ranged from
1.3-9.3 in the MPS I patient group, from 1.0-10.8 in the
MPS II patient group and from 1.9-18.3 in the MPS VI
patient group. In 3 patients, all of whom had MPS VI, the
cardiac signs led to the diagnosis; these were also the only
patients who were using cardiac medication (diuretics and
ACE-inhibitors) at baseline. Due to respiratory failure after
a respiratory infection, one MPS I Hurler patient treated
with ERT died during follow-up at the age of 11 years.
At baseline, 16 of these 24 patients (66%) had an abnor-
mal Z-score for one of the geometric features (LVMI,
LVPWd, IVSd, LVIDd), on echocardiogram. In MPS I and
II, concentric hypertrophy was noted with an increase in
IVSd and to a lesser extent an increase in LVPWd. In MPS
VI, eccentric hypertrophy was observed in three of ten
patients with related increased intraventricular dimensions.
In one of these patients the shortening fraction was de-
creased. LVIDd was increased only in MPS VI patients.
The LVMI ranged from 57 – 268 grams/m2. Twelve of
the 24 patients showed a LVMI Z-score >2. One MPS I
Scheie patient had an increase in LVMI without any other
increased parameters. Figure 1a and b shows an overview of
the Z-scores of the LVMI and the IVSd of all patients by
type of MPS.
At start of therapy, all patients had abnormal valves. An
echocardiogram had been performed in one patient shortly
after birth (at the age of 3 months) and 42 weeks before the
start of enzyme-replacement therapy. In retrospect, it is now
clear that slight echodense abnormalities were already visi-
ble in the mitral valve.
Fifteen patients (63%) had a mild to severe regurgitation
at one or more cardiac valves. The median age of this group
was 5.3 years, whereas the median age of the nine patients
without regurgitation was 2.4 years. Most regurgitation oc-
curred at the mitral and aortic valve. There was regurgitation
at the mitral valve in 7 patients (3 MPS I and 4 MPS VI), at
the aortic valve in 7 patients (2 MPS I, 3 MPS II and 2 MPS
VI), and at the tricuspid valve and pulmonary valve in 2
patients (both MPS VI patients). The most severe regurgi-
tation was in MPS VI patients. All four MPS VI patients
with mitral valve regurgitation had been diagnosed at a
young age (median 2.8 years); in two of them, MPS VI
had been diagnosed after presentation with severe valve
regurgitation. In one of these patient severe mitral regurgi-
tation resulted in severe congestive heart failure. At 8 years
old (one year after the start of enzyme therapy), she underwent
a successful implantation of an artificial valve in mitral
position and a valvuloplasty of the tricuspid valve. Five
patients had a combination of aortic and mitral valve
regurgitation: 1 MPS I Scheie patient, 3 MPS II patients,
and 1 MPS VI patient.
Systolic function was impaired in one Hurler patient
(FS 26%) and two Maroteaux-Lamy patients (FS 30% and
FS 23%). At baseline, the MPS VI patient who required
mitral graft surgery had had a normal shortening fraction
of 36%. E/A ratio as a measure of diastolic function was
abnormal in four patients. None of the patients had pul-
monary hypertension.
Table 2 shows the baseline characteristics of the ECGs,
50% of which showed one or more abnormality. ECG
abnormalities were generally of minor clinical importance.
The effects of enzyme therapy could be reliably evaluated
in 20 patients (see Methods). At start of therapy, 10 patients
had been younger than 5 years: 3 Hurler patients, 2 Scheie
patient, 2 Hunter patients, and 3 Maroteaux-Lamy patients.
Table 1 shows the first and latest results of the echocardio-
grams per patient.
A normal value of IVSd was achieved in 8 of the 10
patients with an IVSd Z-score above 2. At group level, the
decrease in IVSd was significant for the group of MPS II
patients (-0.36 Z-score/year, p00.05). In one MPS I patient
the IVSd Z-score increased over 81 weeks of therapy. This
patient died after 81 weeks of enzyme therapy.
The LVIDd decreased in one patient (MPS VI) with a Z-
score for LVIDd above 2, but deteriorated in two patients
Fig. 1 a and b: Z-score for interventricular septum diameter in diastole
(IVSd) and left-ventricular mass index (LVMI) in the different types of
MPS. The dotted line represents the upper limit of the normal range
(02). One patient (number 24) fell outside the axis range because she
had an LVMI of 26.4 grams/m2
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who had a normal diameter at baseline; in whom an increase
in mitral regurgitation was likely to contribute to the in-
crease in LVIDd.
LVPWd decreased in 4 of 5 patients with a Z-score above
2. The patient who did not respond on IVSd did not respond
on LVPWd either.
Over time, Z-scores could be established reliably in 10 of the
12 patients who had had an LVMI Z-score above 2 at baseline.
Z-scores normalized in 7 of these 10 patients. The decrease in
Z-scores was statistically significant in the MPS I group (−0.31
Z-score/year, p00.04) and the MPS II group (−0.26 Z-score/
year, p00.032). In 4 individual MPS I and VI patients the
decrease in Z-score was significant with values ranging from
0.002 to 0.043. Figure 2 shows their regression lines.
Regurgitation increased after start of ERT in 60% of the
patients and was mostly, in 40% of the cases, seen at the
mitral valve. In most cases regurgitation increased from
none to mild. In one MPS VI patient mitral valve regurgi-
tation increased from moderate to severe; aortic regurgita-
tion increased from mild to moderate in two patients, one
MPS VI and one MPS I patient. In 15% of the patients an
improvement in regurgitation was observed. Patients with
moderate to severe regurgitation did not ameliorate.
Thickness of the mitral valve decreased in 6/20 patients
(1 MPS IS, 2 MPS II and 3 MPS VI), who had been treated
with enzyme therapy for a median of 86 weeks (range of 52-
159 weeks). Eight/20 patients had an increase in mitral
valve thickness (3 MPS I H, 1 MPS I S, 2 MPS II and 2
MPS VI); three of these patients also had an increase in
aortic valve thickness, and had been treated for a median of
110 weeks (range of 48-312 weeks).
The thickness of the aortic valve decreased in 5
patients (2 Hunter and 3 Maroteaux-Lamy patients,
range of therapy 52-159 weeks) and increased in three.
There was no clear relationship between the increase in
thickness of the valves and the development of regurgi-
tation during ERT.
Left ventricular shortening fraction normalized in two of
three patients (FS 35% and 39% at last assessment in
patients 16 and 21), but remained abnormal in the third
(patient 1). The same patients with an impaired diastolic
function at start of therapy continued to have an E/A ratio
<1 at follow-up, except for one patient.
The three MPS VI patients which used medication at start
of therapy remained on medication during the course of
ERT. The dosage could be reduced in one patient, and the
Table 2 Baseline characteristics
on electrocardiography in
24 MPS patients. MPS I
(H/S)0MPS I Hurler and
MPS I Scheie patients.
Bpm0beats per minute
Baseline overall MPS I (H/S) MPS II MPS VI
ECG data
Rhythm
Sinus 24 (100%) 8 (100%) 6 (100%) 10 (100%)
Sinus tachycardia 1 (4%) 1 (13%) 0 (0%) 0 (0%)
Heart rate (bpm) 107 [78-155] 120 [100-155] 118 [80-150] 93 [78-125]
PR interval (ms) 140 [110,180] 130 [120,150] 145 [110,180] 140 [120,180]
Prolonged PR 3 (13%) 0 (0%) 2 (33%) 1 (10%)
QRS duration (ms) 80 [70,100] 80 [70,80] 80 [80-00] 80 [70,100]
Prolonged QRS 3 (13%) 0 (0%) 2 (%) 1 (10%)
QTc interval (ms) 415 [378,453] 402 [390, 417] 440 [412,453] 422 [378, 441]
Prolonged QTc 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Incomplete bundle branch block 2 (8%) 0 (0%) 1 (17 %) 1 (10%)
Left fascicular block 2 1 (13%) 0 (0%) 1 (10%)
Left atrial enlargement 2 (8%) 0 (0%) 1 (17 %) 1 (10%)
Right-ventricular hypertrophy 1 (4%) 1 (13 %) 0 (0%) 0 (0%)
Left-ventricular hypertrophy 1 (4%) 0 (0%) 0 (0%) 1 (10%)
Repolarisation disorder 2 (8%) 0 (0%) 1 (17%) 1 (10%)
Fig. 2 Regression lines of patients with significant improvement in
left-ventricular mass index (LVMI). Z-score LVMI 0 Z-score of the
left-ventricular mass index. ● 0 patient number one (p00.015); ▲ 0
patient number four (p00.002); ○ 0 patient number 21 (p 0 0.009); □ 0
patient number 22 (p00.043)
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medication regiment was changed in one other patient who
received a mitral graft.
No clinically important changes were found at the
follow-up ECGs. We report only the changes found at
follow-up. One patient had atrial beats on the follow-up
electrocardiograms. The increased PR-interval present at
baseline in 2 MPS II patients was absent later. The QRS-
complex increased in duration in the patient who already
had a prolonged QRS at baseline. This was probably due to
the left-ventricular hypertrophy, which was also seen on the
follow-up echocardiogram. Hypertrophy disappeared on
ECG in the only patient who had shown signs of hypertro-
phy on ECG at baseline; this was consistent with the find-
ings on echocardiogram.
Discussion
We studied cardiac abnormalities and the effects of enzyme
therapy in children with MPS I, II and VI. As the current
literature points out, cardiologic abnormalities are a com-
mon finding in patients with MPS (Dangel 1998; Gross et
al. 1988; Rigante and Segni 2002; Wippermann et al. 1995;
Fesslova et al. 2009; Leal et al. 2010; Mohan et al. 2002;
John et al. 1990). At start of therapy, all our patients had
cardiologic abnormalities, which is remarkable, as they were
all relatively young.
At start of therapy, 66% had abnormal cardiac geometric
features caused either by increased cardiac-wall diameter
(IVSd) or by cardiac dilatation. Interestingly, while most
MPS I and II patients had hypertrophic cardiomyopathy –
findings that are consistent with studies reporting the occur-
rence of increased IVSd and left-ventricular hypertrophy in
MPS I and II patients (Dangel 1998; Mohan et al. 2002) -
eccentric hypertrophy was seen solely in the patients with
MPS VI. Reports of ventricular dilatation in MPS VI are still
limited (Leal et al. 2010; Fong et al. 1987; Golda et al. 2011).
Dilatation in our MPS VI patient group was explained mainly
bymitral-valve regurgitation. Primary regurgitation causes the
left-ventricular remodeling and dilatation. Generally in MPS,
we hypothesize that the increase in geometric features is partly
due to the compensatory mechanism caused by the mitral
regurgitation and partly because of the accumulation of stor-
age material. The asymmetric hypertrophy in the wall diame-
ters with an increased IVSd in MPS I and MPS II and an
increased LVIDd in MPS VI indicates this.
While heparan sulphate and dermatan sulphate accumu-
late in MPS I and II, storage in MPS VI is confined to
dermatan sulphate. Leal et al. hypothesized that storage of
dermatan sulphate is the main cause of valve deformation
and dysfunction in MPS (Leal et al. 2010). We in turn
hypothesize that storage of heparan sulphate is an additional
cause of increased thickness of the walls, particularly in the
septum, while the storage of dermatan sulphate leads to
valve impairment and consequent eccentric hypertrophy.
The presence of affected valves in all our patients from
the age of 3 months shows that the deposition of glycosa-
minoglycans in the heart can occur at a very early age, and
may already start in utero; a similar conclusion was drawn
from studies in MPS VII mice (Vogler et al. 2005). The
mitral and aortic valves were the most affected, which is
consistent with earlier reports (Rigante and Segni 2002;
Wippermann et al. 1995). There was no clear relationship
between thickened valves and regurgitation.
Although the most severe valve regurgitation and cardiac
disease occurred in the group of MPS VI patients, this group
also had the least cardiac involvement. Apparently these
patients can be subdivided into two categories: one in which
patients present before the age of 5 years, with cardiac
problems as the main presenting feature; and another in
which clinical features such as joint pains and mobility
problems lead to the diagnosis later in life. While the liter-
ature has concluded that the severity of cardiologic abnor-
malities in MPS VI is either minor (Fesslova et al. 2009;
Mohan et al. 2002) or severe (Dangel 1998; Wippermann et
al. 1995), our results support both conclusions. These differ-
ences may be explained by further genotype-phenotype
studies (Jurecka et al. 2011).
Although 50% of ECGs showed abnormalities, none
showed clinically important rhythm or conduction abnor-
malities. Generally, ECGs did not reflect the hypertrophy
found in patients, possibly because glycosaminoglycans
have a low electric conductance (Rigante and Segni 2002;
Nelson et al. 1990). We therefore conclude that ECG is not a
reliable tool for identifying cardiologic abnormalities in
MPS, and that echocardiography should be mandatory in
all patients. Although conduction abnormalities were not
found in our group of children with MPS, they may occur
at later age (Braunlin et al. 2011). Therefore ECG should
remain part of the follow-up program of MPS patients.
There have been few reports on the effects of enzyme-
replacement therapy on cardiologic abnormalities in MPS
(Braunlin et al. 2006; Fesslova et al. 2009; Scarpa et al.
2009; Kakkis et al. 2001). After ERT, the Z-score normal-
ized in 70% of our patients who had had a Z-score >2 for
LVMI; in four patients this was significant. This suggests
that ERT has some effect on GAG accumulation in cardiac
tissue. Earlier Wraith et al., Braunlin et al. and Okuyama et
al. reported positive or mildly positive effects on the cardiac
diameters in MPS I and II patients (Wraith et al. 2007;
Braunlin et al. 2006; Okuyama et al. 2010).
Effects on cardiac valve regurgitation seem to be limited.
In 60% of patients, valve regurgitation increased, and mitral
valve regurgitation increased in 40%. On the other hand,
15% of patients showed minor improvements in mitral valve
regurgitation. There was no clear relationship between the
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increase in thickness of the valves and the development of
regurgitation during ERT. In some patients, the thickness of
the valves decreased, while in others it increased or stabi-
lized. We should note, however, that 2D imaging is not the
best way of assessing morphologic change. For assessment
of valve morphology, 3D echo currently is the technique of
choice.
Although it is unknown whether the percentage of
patients with dysmorphology and deterioration of valve
regurgitation is similar to that of patients not receiving
ERT (Fesslova et al. 2009; Mohan et al. 2002), our find-
ings suggest overall that the cardiac valves are only
slightly accessible to ERT. This might be explained by
the ultra structure of the cardiac valves. While microvas-
culature can be present in the heart valves, the myofibo-
blasts composing the valves are supplied with oxygen
mainly by diffusion from the valve surface (Misfeld and
Sievers 2007) and therefore not easy targets for the rela-
tively large therapeutic enzymes that need to enter the
cells via receptor mediated endocytosis. As a conse-
quence, the correction of MPS storage in the heart valves
remains challenging. While other studies agree that ERT
has a limited effect on the cardiac valves in MPS I and
MPS II (Fesslova et al. 2009), Scarpa et al. described an
improvement in valve disease in one MPS VI patient in
an Italian cohort (Scarpa et al. 2009).
In our group, 1 MPS I Hurler patient died after a respi-
ratory infection during follow-up. This, notably, was one of
the few patients in whom ERT had no effect on any of the
cardiologic parameters. Further research is required to inves-
tigate the role of prognostic factors.
In conclusion, all MPS I, II and VI patients included
in our study had abnormalities of the valves, 63% had
valve regurgitation, and 66% had one or more abnormal
left ventricular geometric features at an early age. While
ERT seemed to have little or no effect on valve regur-
gitation, it had some effect on cardiac dimensions. Car-
diac disease was most severe in a subset of young MPS
VI patients.
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